Iovance Biotherapeutics to Announce Q2 and H1 2025 Financial Results and Corporate Updates on August 7, 2025

Iovance Biotherapeutics will report Q2 and H1 2025 financial results and corporate updates on August 7, 2025. Management will host a conference call and live audio webcast to discuss these results and provide a corporate update. The company's Amtagvi is the first FDA-approved T cell therapy for a solid tumor indication. Iovance is focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte therapies for patients with cancer.

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a leading biotechnology company specializing in tumor infiltrating lymphocyte (TIL) therapies for cancer treatment, has scheduled its second quarter and first half 2025 financial results announcement for August 7, 2025. The company will host a conference call and webcast at 4:30 p.m. ET to discuss financial performance and provide corporate updates.

The financial results and corporate updates will be hosted on Thursday, August 7, 2025, at 4:30 p.m. ET. Investors can access the webcast through the company's website at IR.Iovance.com, with the recording remaining available for one year.

Iovance Biotherapeutics is committed to innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte therapies for patients with cancer. The company's Amtagvi is the first FDA-approved T cell therapy for a solid tumor indication. Management will discuss the company's financial performance, recent clinical trial outcomes, and strategic initiatives during the conference call.

The appointment of Corleen Roche as Chief Financial Officer, effective August 6, 2025, signifies renewed strategic financial priorities for Iovance. Additionally, positive real-world outcomes for Amtagvi in advanced melanoma have boosted investor optimism for future growth.

For more information, please visit [1] https://www.stocktitan.net/news/IOVA/iovance-biotherapeutics-to-host-second-quarter-and-first-half-2025-o63578qsktjp.html [2] https://www.timothysykes.com/news/iovance-biotherapeutics-inc-iova-news-2025_07_23/.

References:
[1] https://www.stocktitan.net/news/IOVA/iovance-biotherapeutics-to-host-second-quarter-and-first-half-2025-o63578qsktjp.html
[2] https://www.timothysykes.com/news/iovance-biotherapeutics-inc-iova-news-2025_07_23/